📰 Lymphoma Program News
Page 3 - Lymphoma Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lymphoma Program. Real-time updates on events, politics, business and more.
August 3, 2023
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.
June 22, 2023
The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.
June 20, 2023
– Results are from 1,500 patient trial conducted by German Hodgkin Study Group to test ADCETRIS regimen versus international standard eBEACOPP therapy – ADCETRIS regimen showed less... | June 20, 2023
June 17, 2023
The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
June 16, 2023
- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over
June 16, 2023
The FDA has approved glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
June 16, 2023
The drug is a T-cell-engaging bispecific antibody and has been approved for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
June 16, 2023
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.